Avita Medical Ltd.

06/01/2020 | Press release | Distributed by Public on 06/01/2020 20:04

AVITA Medical Files RECELL® System Investigational Device Exemption (IDE) Application with the U.S. Food and Drug Administration for Treatment of Vitiligo